BUR vs PAX

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 3/9 indicating weak financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability margins and a low Price/Book ratio, the company faces severe revenue contraction (YoY growth of -73.60%) and deeply negative earnings surprises, with 11 of the last 12 quarters missing or drastically underperforming estimates. While the stock trades below the Graham Number of $10.01, suggesting slight undervaluation, the weak fundamentals, deteriorating growth, and lack of insider support undermine this. The strong_buy analyst consensus appears overly optimistic given the deteriorating operational performance and bearish technical trend.

PAX presents a dichotomy between poor deterministic value metrics and strong forward-looking analyst sentiment. With a Piotroski F-Score of 5/9, the company's financial health is stable, but it trades at a significant premium to its Graham Number ($7.74) and Intrinsic Value ($4.76). While YoY revenue and earnings growth are sharply negative, the attractive forward P/E of 7.64 and positive Q/Q revenue growth suggest a potential turnaround. The high dividend payout ratio remains a primary concern for long-term sustainability.